Hormone Use among Young People with Gender Incongruence in Norway: A Nationwide Register Study

This nationwide Norwegian register study reveals that the incidence of gender incongruence diagnoses and the prevalence of gender-affirming hormone and puberty blocker use among youth have both increased significantly since 2015, with notable rises among teens assigned female at birth for diagnoses and teens assigned male at birth for puberty suppression.

The Gist

Imagine Norway as a massive, well-organized library. For years, this library has kept detailed records of every person who walks through its doors, noting when they were born, where they live, and what books they check out.

A team of researchers decided to look through these library records to answer a specific question: How many young people in Norway are being diagnosed with gender incongruence (feeling that their internal sense of gender doesn't match the sex they were assigned at birth), and how many of them are using medical treatments like hormones or puberty blockers?

Here is the story of what they found, broken down into simple terms:

1. The "New Arrivals" (Diagnoses)

Think of the "diagnosis" as a young person finally finding the right section in the library to understand themselves. The researchers found that more and more young people are finding this section every year, especially since 2015.

• The Trend: It's like a sudden wave of people walking into the library.
• Who? The biggest jump was seen among teenagers who were assigned female at birth. It's as if a whole new generation of girls is suddenly realizing, "Wait, I belong in a different aisle."

2. The "Tools for the Journey" (Hormone Therapy)

Once someone finds their place in the library, some decide they need special tools to help them feel comfortable in their new skin. These tools are hormones (estrogen for feminizing, testosterone for masculinizing).

• The Trend: The number of young people using these tools has gone up, but with a twist.
• The Analogy: Imagine a school cafeteria. The researchers noticed that while more kids are ordering these special meals, the people eating them are mostly the older teenagers and young adults (like 18 to 24-year-olds), rather than the little kids. It's like the older students are the ones who have been waiting in line the longest and are finally getting served.

3. The "Pause Button" (Puberty Blockers)

For some younger kids, puberty feels like a train moving too fast. Puberty blockers are like hitting the "pause button" on that train, giving them time to figure things out before their bodies change permanently.

• The Trend: Not many kids are using this "pause button" compared to the hormones, but the number is growing, especially since 2015.
• Who? Interestingly, the recent increase in using the "pause button" is happening mostly among teenagers assigned male at birth. It's as if a group of boys who were previously quiet about this are now asking for a moment to pause and think.

The Big Picture

The researchers concluded that there is a clear connection between the two trends:

• As more young people are diagnosed (finding their way in the library), more of them are using medical treatments (getting the tools they need).
• It's not that the treatments are causing the diagnoses, or vice versa; rather, it's a reflection of a society where more young people are feeling safe enough to seek help, and the medical system is there to provide it.

In short: In Norway, more young people are identifying as transgender, and more of them are accessing the medical support they need to live authentically, with the biggest changes happening among older teens and young adults.

Technical Summary

Technical Summary: Hormone Use among Young People with Gender Incongruence in Norway

1. Problem Statement
The study addresses a critical gap in epidemiological data regarding the scale and trends of gender-affirming medical interventions in Norway. While there is a global observation of rising rates of gender incongruence (GI) diagnoses among youth, there is a lack of precise, nationwide data quantifying the actual prevalence of specific medical treatments—specifically puberty blockers, androgens, and estrogens—within this demographic. The research aims to determine the annual, age- and sex-specific prevalence of these interventions among young people with a confirmed GI diagnosis to understand how treatment uptake correlates with diagnostic trends.

2. Methodology
The researchers conducted a nationwide register-based study leveraging the comprehensive nature of Norway's national health and demographic databases.

• Data Sources: The study integrated data from multiple Norwegian national registers.
• Cohort Definition: The study population included individuals with a known sex assigned at birth, born between 1975 and 2017, who were residents of Norway for all or part of the period 2008–2022.
• Diagnostic Criteria: The analysis focused on individuals with a recorded GI diagnosis.
• Intervention Tracking: The study tracked prescription collection for three specific categories:
  • Puberty Blockers: Analyzed for individuals under age 18 in the year of prescription.
  • Androgens and Estrogens: Analyzed for individuals under age 25 in the year of prescription.
• Statistical Approach: The researchers calculated:
  1. Annual incidence of GI diagnoses in the general population.
  2. Annual prevalence of hormone and blocker use specifically within the diagnosed cohort, stratified by age and sex assigned at birth.

3. Key Contributions

• Granular Epidemiological Data: This is one of the few studies to provide high-resolution, nationwide data linking GI diagnoses directly to the utilization of specific medical interventions (blockers vs. cross-sex hormones) over a 14-year period.
• Demographic Stratification: By breaking down data by age, sex assigned at birth, and specific intervention type, the study offers nuanced insights into how different subgroups access care, moving beyond aggregate national statistics.
• Temporal Analysis: The study captures a significant longitudinal window (2008–2022), allowing for the identification of inflection points in healthcare utilization trends.

4. Results

• Diagnostic Incidence: There was a marked increase in the incidence of GI diagnoses among youth in Norway. This trend accelerated significantly after 2015, with the most substantial rise observed among teens assigned female at birth (AFAB).
• Hormone Therapy Prevalence: The prevalence of both feminizing (estrogen) and masculinizing (androgen) hormone therapy increased during the study period. However, this increase was concentrated among the oldest teens and young adults (approaching the upper age limits of the study cohort), rather than younger adolescents.
• Puberty Blocker Usage: The overall prevalence of puberty suppression remained low compared to hormone therapy. However, usage has increased since 2015, with a notable recent rise specifically among teens assigned male at birth (AMAB).

5. Significance
The study provides empirical evidence that the rise in gender-affirming care in Norway is concurrent with a rise in GI diagnoses, confirming a correlation between diagnostic identification and medical intervention.

• Policy and Planning: The data highlights a shifting demographic in treatment seekers (e.g., the surge in AFAB diagnoses and the specific rise in blockers for AMAB), which is essential for healthcare planners to allocate resources effectively.
• Clinical Context: The finding that hormone therapy is more prevalent among older youth, while blocker use is low but rising among specific subgroups, helps clinicians and policymakers understand the current stage of care delivery in the Norwegian system.
• Global Relevance: As a nationwide study with near-complete population coverage, it serves as a robust reference point for international comparisons regarding the epidemiology of transgender healthcare in high-income, universal healthcare systems.